Phytopharm updates on Cogane and Myogane development progress
UK drug developer Phytopharm (LSE: PYM) yesterday presented its interim management statement for the four and a half months to August 16, noting the progress being made with its lead drug candidates, Cogane (PYM 50028) and Myogane (PYM 50018).
Cogane in Parkinson’s disease
The company noted that Cogane is currently being evaluated in a 400 patient multi-national Phase II, randomized, double blind, placebo controlled, dose ranging study (CONFIDENT-PD). Patient recruitment commenced in November 2010, and Phytopharm its target remains to have headline results from the study available at the end of 2012.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze